# SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects

> **NCT03383302** · PHASE1,PHASE2 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 29 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage II
- Non-small Cell Lung Cancer Stage I

## Interventions

- **RADIATION:** Stereotactic body radiotherapy
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03383302
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-08
- **Primary completion:** 2024-08-12
- **Final completion:** 2025-06-26
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383302, "SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03383302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*